Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2026)

Rigel Pharmaceuticals' Non-Current Debt history runs 8 years deep, the most recent figure standing at $44.9 million for Q1 2026.

• In Q1 2026, Non-Current Debt changed 0.17% year-over-year to $44.9 million; the TTM figure through Mar 2026 stood at $44.9 million (changed 0.17% YoY), while the FY2025 annual figure was $22.5 million, down 57.1% from the prior year.
• Non-Current Debt was $44.9 million for Q1 2026 at Rigel Pharmaceuticals, up from $22.5 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $59.8 million in Q3 2024 to a low of $22.5 million in Q4 2025.
• Historically, Non-Current Debt has averaged $45.1 million across 5 years, with a median of $44.9 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Non-Current Debt jumped 99.68% in 2023, then sank 57.1% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $39.4 million in 2022, then jumped by 32.76% to $52.4 million in 2023, then climbed by 0.07% to $52.4 million in 2024, then tumbled by 57.1% to $22.5 million in 2025, then soared by 99.52% to $44.9 million in 2026.
• The last three Non-Current Debt figures came in at $44.9 million (Q1 2026), $22.5 million (Q4 2025), and $30.0 million (Q3 2025), per Business Quant data.